SG11202100575QA - Pyridopyrimidines as histamine h4-receptor inhibitors - Google Patents

Pyridopyrimidines as histamine h4-receptor inhibitors

Info

Publication number
SG11202100575QA
SG11202100575QA SG11202100575QA SG11202100575QA SG11202100575QA SG 11202100575Q A SG11202100575Q A SG 11202100575QA SG 11202100575Q A SG11202100575Q A SG 11202100575QA SG 11202100575Q A SG11202100575Q A SG 11202100575QA SG 11202100575Q A SG11202100575Q A SG 11202100575QA
Authority
SG
Singapore
Prior art keywords
pyridopyrimidines
histamine
receptor inhibitors
inhibitors
receptor
Prior art date
Application number
SG11202100575QA
Inventor
Herrero Gonzalo Hernández
Domínguez Neftalí García
Arce Arturo Zazpe
Tizne Roberto Olivera
Pedro Bárbara Noverges
Vivar Reyes Corcóstegui
Cerdeiras Paloma Tato
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of SG11202100575QA publication Critical patent/SG11202100575QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202100575QA 2018-07-25 2019-07-24 Pyridopyrimidines as histamine h4-receptor inhibitors SG11202100575QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382559 2018-07-25
PCT/EP2019/069905 WO2020020939A1 (en) 2018-07-25 2019-07-24 Pyridopyrimidines as histamine h4-receptor inhibitors

Publications (1)

Publication Number Publication Date
SG11202100575QA true SG11202100575QA (en) 2021-02-25

Family

ID=63207688

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100575QA SG11202100575QA (en) 2018-07-25 2019-07-24 Pyridopyrimidines as histamine h4-receptor inhibitors

Country Status (27)

Country Link
US (1) US20210300922A1 (en)
EP (1) EP3827005B1 (en)
JP (1) JP7093462B2 (en)
KR (1) KR102603203B1 (en)
CN (1) CN112739699B (en)
AU (1) AU2019310889B2 (en)
BR (1) BR112021001270A2 (en)
CA (1) CA3107556C (en)
CL (1) CL2021000184A1 (en)
CO (1) CO2021001925A2 (en)
DK (1) DK3827005T3 (en)
EA (1) EA202190339A1 (en)
EC (1) ECSP21010874A (en)
ES (1) ES2929227T3 (en)
HR (1) HRP20221250T1 (en)
HU (1) HUE059824T2 (en)
LT (1) LT3827005T (en)
MA (1) MA53372B1 (en)
MX (1) MX2021000966A (en)
PE (1) PE20211638A1 (en)
PH (1) PH12021550143A1 (en)
PL (1) PL3827005T3 (en)
PT (1) PT3827005T (en)
RS (1) RS63661B1 (en)
SG (1) SG11202100575QA (en)
WO (1) WO2020020939A1 (en)
ZA (1) ZA202101092B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56020A (en) * 2019-05-31 2022-04-06 Chiesi Farm Spa PYRIDOPYRIMIDINE DERIVATIVES USED AS P2X3 INHIBITORS
JP2023084709A (en) * 2020-04-28 2023-06-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Novel bicyclic compound having histamine h4 receptor-regulating effect

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789399A1 (en) 2004-08-31 2007-05-30 AstraZeneca AB Quinazolinone derivatives and their use as b-raf inhibitors
JP2008280341A (en) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd Hydrazide compound and its use in controlling harmful organism
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
CA2737217A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
JP6535430B2 (en) * 2012-09-28 2019-06-26 イグニタ、インク． Azaquinazoline inhibitors of atypical protein kinase C

Also Published As

Publication number Publication date
KR20210038909A (en) 2021-04-08
BR112021001270A2 (en) 2021-04-20
MA53372B1 (en) 2022-10-31
EP3827005A1 (en) 2021-06-02
PL3827005T3 (en) 2022-11-28
AU2019310889A1 (en) 2021-03-11
DK3827005T3 (en) 2022-09-19
WO2020020939A1 (en) 2020-01-30
PH12021550143A1 (en) 2021-09-13
JP2021531304A (en) 2021-11-18
CN112739699B (en) 2023-11-28
AU2019310889B2 (en) 2022-03-31
LT3827005T (en) 2022-11-10
ES2929227T3 (en) 2022-11-25
EP3827005B1 (en) 2022-08-17
CN112739699A (en) 2021-04-30
US20210300922A1 (en) 2021-09-30
CA3107556A1 (en) 2020-01-30
NZ773053A (en) 2023-10-27
PE20211638A1 (en) 2021-08-24
CL2021000184A1 (en) 2021-07-09
MA53372A (en) 2021-06-02
ECSP21010874A (en) 2021-03-31
RS63661B1 (en) 2022-11-30
MX2021000966A (en) 2021-07-06
HRP20221250T1 (en) 2022-12-09
ZA202101092B (en) 2022-09-28
PT3827005T (en) 2022-11-04
HUE059824T2 (en) 2023-01-28
CA3107556C (en) 2022-10-25
EA202190339A1 (en) 2021-05-20
CO2021001925A2 (en) 2021-03-08
JP7093462B2 (en) 2022-06-29
KR102603203B1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
IL277006A (en) Cd73 inhibitors
IL304348A (en) Cd73 inhibitors
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
GB201705263D0 (en) Novel inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
ZA201907136B (en) Ip6k inhibitors
IL276013A (en) Pi4kiiibeta inhibitors
ZA202101092B (en) Pyridopyrimidines as histamine h4-receptor inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL274550A (en) Dopamine-b-hydroxylase inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors